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Abstract
Background:  In lymphocyte subsets, expression of CD56 (neural cell adhesion molecule-1)
correlates with cytotoxic effector activity. For cells bearing the Vγ2Vδ2 T cell receptor, isoprenoid
pyrophosphate stimulation leads to uniform activation and proliferation, but only a fraction of cells
express CD56 and display potent cytotoxic activity against tumor cells. Our goal was to show
whether CD56 expression was regulated stochastically, similar to conventional activation antigens,
or whether CD56 defined a lineage of cells committed to the cytotoxic phenotype.
Results: Tracking individual cell clones defined by their Vγ2 chain CDR3 region sequences, we
found that CD56 was expressed on precursor cytotoxic T cells already present in the population
irrespective of their capacity to proliferate after antigen stimulation. Public T cell receptor
sequences found in the CD56+ subset from one individual might appear in the CD56- subset of
another donor. The commitment of individual clones to CD56+ or CD56- lineages was stable for
each donor over a 1 year interval.
Conclusion: The ability to express CD56 was not predicted by TCR sequence or by the strength
of signal received by the TCR. For γδ T cells, cytotoxic effector function is acquired when cytotoxic
precursors within the population are stimulated to proliferate and express CD56. Expression of
CD56 defines a committed lineage to the cytotoxic phenotype.
Background
Potent effector cells among CD8+ αβ T cells, NK cells,
NKT cells and γδ T cells each have specific mechanisms for
identifying malignant or infected targets and sparing nor-
mal cells. Common to all is the expression of CD56 (neu-
ral cell adhesion molecule 1; NCAM-1) on the effector cell
subset [1-5]. For example, CD56+ CD8+ T cells with high
expression of perforin and Granzyme B are potent cyto-
toxic effectors that possess an oligoclonal Vβ chain reper-
toire [2]. NK cells lack T cell receptors (TCR) and rely
instead on complex families of NKR and KIR molecules to
identify target cells [6,7]. The NKT cells express an invari-
ant Vα24 chain that is responsible for their CD-1
restricted responses to Galactosyl ceramide [8,9].
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We are trying to understand tumor cell recognition by
human Vγ2Vδ2 T cells (also called Vγ9Vδ2 in an alternate
nomenclature). This population is dominated by cells
expressing the Vγ2-Jγ1.2 rearrangement which endows the
MHC-unrestricted response to isoprenoid pyrophos-
phates (phosphoantigens) or synthetic aminobisphos-
phonates that cause accumulation of phosphoantigens,
and specific human tumor cell lines [10-13]. Despite com-
plexity of the Vγ2 chain CDR3 region [14-16], individual
cell clones respond similarly to phosphoantigens or
tumor cells [13] and it remains unclear how activated
Vγ2Vδ2 cells discriminate normal from malignant cells
and what controls cytotoxicity.
Recently, we [17] reported that CD56 was expressed on a
potently cytotoxic subset of human Vγ2Vδ2 T cells, similar
to what was reported for CD8 T cells [2]. However, strong
proliferation responses to phosphoantigen occurred in
both CD56+ and CD56- populations. This highly selected
oligoclonal Vγ2Vδ2 + population responds uniformly to
phosphoantigen, yet only ~50% of expanded cells express
CD56 and lyse tumor cell targets. We imagined three alter-
native models to explain these observations: 1) CD56
expression is regulated stochastically perhaps by cytokine
signals; 2) Vγ2Vδ2 T cell receptors vary in strength or spe-
cificity of antigen binding and these properties are related
to control of CD56 expression; 3) CD56 is expressed only
on CTL precursors that represent distinct subsets or line-
ages.
Our initial approach for defining the CD56+ subpopula-
tion used Vγ2 sequences as markers for individual T cell
clones. Vγ2Vδ2 T cell lines were generated from PBMC by
phosphoantigen treatment and separated into CD56+ and
CD56- fractions. A sample of Vγ2 chains from each frac-
tion was cloned and sequenced. If the same Vγ2 sequences
are detected in both fractions, expression of CD56 must
be regulated stochastically, in accordance with model 1
(above). If the Vγ2 chain repertoire is distinct between the
CD56+ and CD56- fractions, we need to test whether a
previously missed antigen specificity within the Vγ2Vδ2
repertoire dictates CD56 expression and tumor cell cytol-
ysis. For testing the latter, we can exploit the observation
that human Vγ2 repertoire has a high proportion of public
clonotypes with complete CDR3 region identity among
unrelated individuals [13]. By comparing phenotypes for
cells expressing public clonotypes, in terms of whether
they express CD56 similarly among unrelated individuals,
we learn whether TCR specificity dictates CD56 expres-
sion.
Our results argue that individual Vγ2Vδ2 T cell clones are
already committed to either the CD56+ or CD56- subset.
Commitment is not due to special properties of the TCR
but seems, within the limits of our analysis, to be a prop-
erty distinct to each clone. The circulating Vγ2Vδ2 T cell
pool is the result of chronic, positive selection [18] and
individual clones seem to be long-lived--at least 7 years in
adults [13]. Thus, the mechanisms controlling CD56
expression can have long-term impact on the capacity for
tumor cell cytotoxicity.
Methods
PBMC Isolation, In vitro IPP stimulation and expansion of 
Vγ2Vδ2 T cells
Whole blood was obtained with written consent from
healthy human volunteers and approved by the Institu-
tional Review Board at the University of Maryland School
of Medicine. Donors studied here are representative of the
specimen collection in our laboratory. Total lymphocytes
were separated from heparinized peripheral blood by
density gradient centrifugation (Ficoll-Paque; Amherson
Biosciences, Piscataway, NJ). Isolated PBMC were then
cultured at 1 × 106 cells/ml in RPMI-1640 media supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 U/ml streptomycin (GIBCO, Grand
Island, NY) and 100 U/ml recombinant human inter-
leukin-2 (rIL-2) (Tecin, Biological Resources Branch, NIH,
Bethesda, MD). To stimulate PBMC, 15 μM of isopentenyl
pyrophosphate (IPP) (Sigma, St. Louis MO) were added.
Cultures were incubated for 14 days at 37°C with 5% CO2
and media with IL-2 was replenished every 3-4 days. Cell
proliferation was confirmed by flow cytometry using
monoclonal antibodies specific for Vγ2 (FITC), CD56
(PE), CD3 (APC), and isotype-matched, IgG controls. At
least 1 × 104 lymphocytes were analyzed per sample on a
FACSCalibur flow cytometer (BD Biosciences, San Diego,
CA). Flow cytometry data were analyzed using FlowJo
software.
Cell Separation and DNA Synthesis
Fresh PBMC and cell lines obtained after IPP stimulation
were separated into CD56+ and CD56- populations using
magnetic bead techniques. Specifically, 1 × 107 to 2 × 107
cells were treated with anti-CD56 conjugated to PE (Beck-
man Coulter, Inc) at 15 μl/107 cells, followed by mag-
netic-bead labeled anti-PE (Miltenyi Biotec., Auburn, CA)
at 30 μl/107 cells. Labeled cells were passed through a
magnetic column and fractions were collected. This proce-
dure was repeated to achieve highest possible purity. Total
RNA was extracted from at least 1 × 106 CD56+ or CD56-
cells using RNeasy Mini Kits (Qiagen, Valencia, CA)
according to the manufacturer's instructions. One μg of
total RNA was converted to cDNA using a reverse tran-
scription kit (Promega, Madison, WI). Each reaction was
incubated at 42°C for 120 min and then diluted with
RNAse/DNase free H2O to a total volume of 100 μl. Five
μl of cDNA served as the template for subsequent PCR
reaction to amplify the Vγ2 T cell chain using 2.5 μM Vγ2
forward primer (5'-atcaacgctggcagtcc-3') and 2.5 μM Cγ1BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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reverse primer (5'gttgctcttcttttcttgcc-3') under the follow-
ing cycling conditions: 5 min denaturation at 94°C, 30
cycles of 1 min at 94°C, 1 min at 60°C, and 1 min at
72°C, followed by a final elongation for 10 min at 72°C
AmpliTaq Gold (Applied Biosystems, Inc., Branchburg,
New Jersey).
Cloning and Sequencing
PCR products were separated on 1% agarose gels and puri-
fied using a QIAquick gel extraction kit (Qiagen) accord-
ing to the manufacturer's instructions. Purified products
were denatured for 1 min at 94°C, incubated for 30 min
at 72°C with 2 mM MgCl2, 0.2 mM dATPs, 2.5 U Ampli-
Taq Gold, then ligated into the pCR2.1 cloning vector.
The ligated vector was transfected into TOP10F' compe-
tent E. coli cells (TA Cloning Kit, Invitrogen, Carlsbad,
CA) and bacterial colonies were grown overnight on agar
plates containing 50 μg/ml ampicillin, 500 μM isopro-
pylthiogalactoside (IPTG) and 80 μg/ml 5-bromo-4-
chloro-3-indolyl-B-D-galactopyranoside (X-Gal). White
colonies, containing the recombinant plasmid, were cul-
tured overnight in LB supplemented with 50 μg/ml ampi-
cillin, then plasmid DNA was purified using Real 96
Miniprep kits (Qiagen). Sequencing reactions used the Big
Dye v3.1 fluorescent sequencing kit (Applied Biosystems,
Foster City, CA) with the M13 forward and reverse oligo-
nucleotide primers. Sequences were analyzed on an
ABI3700 sequencer and aligned using Sequencher and
MacVector software. In total, approximately 5,000 Vγ2
sequences were annotated, aligned and compared during
this study.
Daudi Cultures
The B cell lymphoma cell line, Daudi, was obtained from
ATCC (CCL-213). Cells were cultured at 37°C with 5%
CO2 at a concentration between 3.5 × 105 to 1 × 106 cells/
ml. Cultures were kept in RPMI-1640 media supple-
mented with 10% FBS, PCR extension temp to 72°, 2 mM
L-glutamate, 4.5 g/L glucose, 1.5 g/L NaHCO3, 10 mM
HEPES, and 1 mM sodium pyruvate (GIBCO). Cells were
cultured for no more than 20 passages.
γδ T Cell Cloning
γδ T cells clones were obtained following a previously
published procedure [15], with some modifications. Spe-
cifically, PBMC were isolated from whole blood as
described above. Using the MACS system and the Vγ2
monoclonal antibody conjugated to PE, we isolated the
Vγ2 + fraction of cells. The cells were incubated in media
overnight at 37°C with 5% CO2. In a 96-well V-bottom
microtiter plate (Corning, NY), 1 cell/well of the Vγ2+
population was obtained by limiting dilution and com-
bined with 1 × 105/well irradiated (5000 rad) autologous
PBMC and 1 × 104/well irradiated (5000 rad) Daudi in a
total volume of 100 μl. 15 μM IPP and 100 U/ml IL-2 was
also added to each well. The plates were incubated for 21
days at 37°C with 5% CO2. Wells that showed signs of cell
proliferation were analyzed by flow cytometry for expres-
sion of Vγ2, Vδ2, CD56, NKG2D, and NKG2A (BD Bio-
sciences). Clonality of the population was determined by
sequencing of the Vγ2 CDR3 region.
Flow Cytometric Cytotoxicity Assay
Due to the low cell numbers generated by cloning, and the
fragility of the cloned γδ T cells when re-expanded, cyto-
toxicity of the individual γδ T cell clones was measured
using a flow cytometry based assay. In this assay, 1 × 103
Daudi target cells were labeled with CFSE (Cell Trace™,
Invitrogen) and then combined in a 96-well microtiter
plate (Corning) with Vγ2 cell effectors at effector to target
ratios varying from 10:1 to 0.1:1. Reactions to control for
spontaneous lysis included only the CFSE-labeled targets
and medium. Plates were incubated at 37°C with 5% CO2
for 4 hours. After the incubation, 10 ul of 18% parafor-
maldehyde in phosphate-buffered saline were added to
inactive effector cells, then we added 2.5 × 103 Daudi cells
that had been labeled with PKH26 (Sigma Corp., St.
Louis, Missouri). Cells were then analyzed by flow cytom-
etry, measuring the proportions of green (CFSE) and red
(PKH26) labeled Daudi cells. A decrease in the proportion
of green:red indicated cytotoxicity of the added Vγ2+ cells.
Specific lysis was determined by comparing the ratio of
PKH26-labeled reference cells with CFSE-labeled target
cells in the following formula: (CFSE:PKH26 control -
CFSE target:PKH26 reference) × 100.
Results
Asymmetric CD56 expression in Vγ2Vδ2 T cells
The Vγ2Vδ2+ cell lines obtained after phosphoantigen
stimulation of PBMC contain CD56+ and CD56- subsets.
These subsets were separated by magnetic bead sorting
and the TCR repertoire was characterized by cloning and
sequencing a sample of the Vγ2 chains in each fraction.
The DNA sequences were aligned and translated into
amino acid sequences representing the individual clono-
types found for each donor. The most abundant clono-
types from each donor and whether they appear in CD56+
or CD56- fractions are shown (Figure 1).
As expected, we found both private (unique to one donor)
and public (found in more than one donor) clonotypes
among these Vγ2 chains. Public clonotypes match at all
positions including the CDR3 region encoded partly by
non-templated nucleotides. Public Vγ2 clonotypes found
in these data sets include WEV---QELG, WEV---R---ELG
and WE---A---QELG. We refer to WEV---QELG as the
"canonical" clonotype because it is mostly encoded by
germline sequences without deletion of V or J segments
and without nucleotide additions. Among 8 donors, pub-
lic Vγ2 clonotypes appeared 18 times. In 12 of 18 exam-BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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ples, the clonotypes appeared in both CD56+ and CD56-
fractions with < 2-fold difference in frequency between
the 2 fractions. In the remaining 6 of 18 (33%) appear-
ances, the public clonotype was more abundant in either
CD56+ or CD56- fractions--a condition referred to as
asymmetry. Among these 8 donors, we found 28 highly
abundant private Vγ2 clonotypes. Of the private clono-
types, 21 (75%) were distributed asymmetrically (>2-fold
difference).
These data suggested that public clonotypes were associ-
ated randomly with CD56+ or CD56- fractions or distrib-
uted symmetrically, but private clonotypes were
distributed asymmetrically into the two subsets. However,
only a single sample from each donor was analyzed, so we
could not determine if the association with CD56 expres-
sion was stable. To address this issue, we needed to con-
centrate on a smaller number of donors to complete more
extensive studies including replicate sampling. We
selected donors ND001, ND006 and ND019 as represent-
atives of the donor pool.
Stably expressed Vγ2 chain sequences can be used to 
compare CD56+ and CD56- subsets
We compared Vγ2 clonotype (the amino acid sequence for
the Vγ2 chain CDR3 region) frequencies among three
healthy donors in samples collected approximately 1 year
apart using 200-300 Vγ2 chain cDNA clones from each
specimen. The Vγ2 chain cDNA from PBMC or IPP-stimu-
lated cell lines were cloned into plasmids and sequenced
individually. The frequencies for individual Vγ2 clono-
types were calculated as a proportion of the total number
Asymmetric CD56 Expression in Vγ2Vδ2 T cells Figure 1
Asymmetric CD56 Expression in Vγ2Vδ2 T cells. IPP-stimulated cell lines were generated from 8 normal human donors 
and fractionated by magnetic bead separation into CD56+ and CD56- subsets. Vγ2 chains from each fraction were sequenced 
and translated. The frequency of each chain, identified by their unique CDR3 regions, with the fraction was calculated. Clono-
types found at a frequency below 3% were below the levels of detection for this assay, since below that cutoff we cannot 
reproducibly detect them. Clonotypes were considered committed to either the CD56+ or CD56- populations if the distribu-
tion was greater than 2:1. Black shading identifies clonotypes committed to CD56+ population, while those committed to the 
CD56- population are shaded in gray.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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of sequences obtained from each cell sample. Only clono-
types found at a frequency of 3% or greater were studied;
below that level, frequency values are less reproducible
due to sampling errors. Clonotypes detected in IPP-
expanded lines from both 2007 and 2008 time points
were also deemed stable. Frequencies for each stable
clonotype from three donors ND001, ND006, and
ND019 are shown (Table 1). In each case, the prolifera-
tion response to IPP was similar at both time points for
each clonotype.
CD56 positive and negative fractions from individual 
donors contain distinct Vγ2 clonotypes
We next measured the frequencies for individual clono-
types in CD56+ and CD56- subsets. PBMC collected 1
year apart and the resulting IPP-expanded cell lines were
fractionated into CD56+ and CD56- populations using
magnetic bead cell separation. The Vγ2 chain mRNAs were
amplified by PCR, cloned in plasmid vectors and
sequenced to determine the frequency of individual Vγ2
clonotypes within the population.
The most common Vγ2 clonotypes from donors ND001,
ND006, and ND019 are shown (Figure 2A). If a particular
clonotype was more abundant in one fraction by a differ-
ence greater than 2:1, it was assigned as CD56+ or CD56-
as appropriate. Clonotype distributions varied among
donors. In ND001, 5 out of 7 (71.4%) stable clonotypes
expanded preferentially into either CD56+ or CD56- frac-
tions. In ND006 and ND019, 1 of 4 (25%) and 2 of 6
(33.3%) stable clonotypes showed this asymmetry. The
patterns for clonotype distribution were consistent over
the 1-year sampling period. For example, the ND001
clonotype CALW---SR---ELG was 8 times more frequent in
the 2007 CD56+ fraction and was 10 times more frequent
in 2008. CALWE---TE---ELG was in the CD56- population
at similar frequencies for both time points.
We next looked at clonotypes where there was no clear
bias toward CD56+ or CD56- fractions (Figure 2B), the
so-called "inconclusive" clonotypes. Many of these are
public clonotypes that is, they are present in more than
one donor. In our experience, public clonotypes are usu-
ally encoded by more than one nucleotide sequence
(nucleotypes). We examined Vγ2 nucleotypes for each
public clonotype and calculated their respective frequen-
cies (Figures 3, 4 &5). Nucleotype analysis explained the
behavior for some of the inconclusive clonotypes. For
example, the ND019 clonotype CALWE---A---QELG was
skewed to the CD56+ population in a 2007 IPP-expanded
specimen, but was less biased in a 2008 sample (Figure
2B). Singling out its most abundant nucleotype, GCC---
CAA, we see it was skewed to the CD56+ population in
both samples at frequencies of 12% to < 3% and 6% to <
3%, respectively (Figure 3). Clearly, this nucleotype was
committed to the CD56+ phenotype even if the overall
clonotype appeared unbiased. Other nucleotypes (GCT---
CAA and GCG---CAA) behaved differently in the 2007
and 2008 specimens causing them to appear inconclusive
i.e., observable in both CD56+ and CD56- fractions. The
ND019 clonotype CALWEV---R---ELG was found in both
CD56+ and CD56- populations. However, we identified a
major nucleotype, GTG---CGA that was more common in
the CD56- population (Figure 4). Again the distinct
behavior of individual nucleotypes confused the clono-
type analysis. We cannot always analyze the distribution
of every nucleotype within a public clonotype because
some are infrequent, but this level of analysis supported
the view that CD56 expression is not a random marker
and most of the individual nucleotypes each have distinct
expression of CD56.
Nucleotype analyses explained most but not all of the
inconclusive clonotypes. The public canonical sequence,
CALWEV---QELG, is the Vγ2-Jγ1.2 germline sequence
without junctional nucleotides. It was not consistently
segregated into CD56+ or CD56- fractions for any donor
at the clonotype (Figure 2B) or nucleotype (Figure 5) lev-
els. Early γδ cell ontogeny is characterized by a high fre-
quency of canonical recombinations [19]. Therefore, the
presence of this Vγ2 chain sequence does not imply clon-
ality because it likely arises again and again throughout
life. Other inconclusive clonotypes, such as CALWEV---D-
--ELG and CALWEV---RK---LG were distributed differently
in 2008 compared with the 2007 specimens. These clono-
types are each encoded by a single nucleotype, implying
they represent a single clone of cells. Whether clones can
change in terms of the capacity to express CD56 or
whether new clones arose with the same nucleotype, can-
not be discerned from our data. However, most of the
clones we observed had the same phenotype in PBMC col-
lected 1 year apart and the capacity for CD56 expression
appears to be stable.
Identical Vγ2 nucleotypes are present among unrelated 
donors
We observed a number of identical Vγ2 chains among
unrelated donors. For example, the nucleotype GTG---
CGG---GAG was in all 3 donors (Figure 4). In ND006, it
was the most abundant nucleotype encoding the public
clonotype CALWEV---R---ELG. In donor ND019, it was
equally abundant as the GTG---CGA---GAG nucleotype.
Individual nucleotypes encoding the public clonotype
CALWE---A---QELG were also found in multiple donors
(Figure 3). The canonical nucleotype (GTG---CAA) was
abundantly present in all 3 donors, but this was not sur-
prising, given the high frequency of canonical recombina-
tions during ontogeny. Interestingly, the canonical
clonotype (WEV---QELG) was not always the product ofBMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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Table 1: Stable Clonotypes.
Clonotypes Ex Vivo IPP Expand
DONOR: ND001 2007 2008 2007 2008
CALW SR ELG 52 34 13 21
CALWE A ELG 14 28 11 14
CALWE RK QELG <3 <3 6 3
CALWEV RK LG 3659
CALWEV QELG 4< 35 4
CALWE T QELG <3 <3 11 21
CALWE TE QELG <3 <3 6 10
N 165 158 151 239
DONOR: ND006
CALWEV QELG 11 13 11 13
CALWE AK ELG <3 9 5 10
CALWE A QELG 11 6 5 12
CALWEV R ELG < 3 464
N 156 206 186 287
DONOR: ND019
CALWEV D ELG 28 36 36 23
CALWE PQ QELG 1 0 547
CALWEV QELG 7947
CALWEV R ELG 6338
CALWE A QELG 8895
CALWE IE QELG <3 <3 6 5
N 163 256 166 246
Vγ2 chain clonotypes (CDR3 region) are shown for donors ND001, ND006 and ND019. For each clonotype, we show the proportion of all Vγ2 
chains represented by that clonotype for specimens collected in 2007 or 2008. Clonotype abundance for ex vivo and post-expansion samples are 
shown. The N values represent the total number of Vγ2 chain DNA sequences obtained for each specimen.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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germline sequences, as non-canonical nucleotypes also
encoded this chain (Figure 5).
Vγ2 chain sequence did not predict CD56 expression
We evaluated in three donors whether public clonotypes
appear consistently in either CD56+ or CD56- subsets.
The clonotype CALWE---A---QELG is a useful example
(Figure 3). In ND001, this clonotype (represented by the
dominant nucleotype GCG---CAA) was predominantly in
the CD56- population. In ND019 the dominant nucleo-
type (GCC---CAA) was in the CD56+ population. ND006
is unusual in that the clonotype's dominant nucleotype
(GCT---CAA) was in the CD56- population of the 2007
sample and in the CD56+ population of 2008. This sug-
gests that individual clones can switch to a different com-
mitted phenotype or a new clone arose with the same
CDR3 region sequence. Since we have observed identical
nucleotypes in unrelated donors, it is assumed that the
same sequences can be generated more than once in a sin-
gle donor and we expect to find some nucleotypes with
inconsistent behavior.
Our data suggest that the ability of Vγ2Vδ2 T cells to
express CD56 can be separated from the strength of pro-
liferative responses received through the TCR. After
expanding the Vγ2Vδ2 subset by IPP, the ND001 clono-
type CALW--SR---ELG increased to 21.3% of the Vγ2 posi-
tive population (Table 1). The CALWE---T---QELG
expressing cells also increased to a frequency of 21%.
However, the expanded CALW---SR---ELG cells expressed
CD56, and the CALWE---T---QELG cells remained CD56
negative (Figure 2A). We have observed examples of rap-
idly proliferating cells in both CD56+ and CD56- subsets
and strength of response to phosphoantigen does not
appear to influence CD56 expression.
IL2 alone induces CD56 expression, but the repertoire is 
distinct from phosphoantigen expanded cell lines
We noted that culture with IL-2 alone did not expand the
Vγ2+ cells (Figure 4A) but did induce CD56 expression on
Vγ2Vδ2 cells (Figure 4B). IL-21, a cytokine that enhances
both proliferation and effector functions of αβ T cells and
another member of the common γ chain cytokines, also
induced CD56 expression on γδ T cells [20]. This suggests
that signaling through the Vγ2Vδ2 TCR is not required for
expression of CD56 and encouraged us to understand the
clone complexity of IL-2-treated CD56+ cells. We com-
pared the Vγ2 repertoire of CD56-depleted PBMC treated
with IL-2 alone to the IPP-expanded cell lines to test this
hypothesis.
We depleted CD56+ cells from PBMC with magnetic bead
separation. The remaining CD56- cells were treated with
IL-2. The IL-2 alone caused little to no proliferation of the
Vγ2+ population. In contrast, IPP + IL-2 stimulation
caused significant expansion, with Vγ2+ cells making up
40 to 90% of PBMC by 14 days after stimulation (Figure
6A). Despite the lack of significant expansion, by day 14
the IL-2-only treated Vγ2 cells had increased expression of
CD56 (Figure 6B). We next tested whether similar clono-
types were present in CD56+ or CD56- fractions after IL-2
alone compared to IPP + IL-2 stimulation.
Clonotype frequencies were starkly different for the IL-2
treated PBMC compared with cell lines obtained after IPP
+ IL-2 (Table 2). CALWEV---D---ELG was the dominant
clonotype in PBMC from ND019 and IPP-expanded Vγ2
cells with frequencies of 36% and 23% respectively. In the
Conclusive and Inconclusive Clonotypes Figure 2
Conclusive and Inconclusive Clonotypes. Ex vivo PBMC 
and IPP-expanded cell lines were fractionated by magnetic 
bead cell separation into CD56+ and CD56- populations. 
RNA was extracted and converted to DNA. Vγ2 chains were 
sequenced and the frequency of clonotypes within each pop-
ulation was calculated. Limit of detection of this assay was 
>3%. Clonotypes were considered committed to either the 
CD56+ or CD56- populations if the distribution was greater 
than 2:1 (Conclusive); the remaining clones were considered 
Inconclusive as there was no clear bias in their distribution. 
Black shading identifies clonotypes committed to CD56+ 
population, while those committed to the CD56- population 
are shaded in gray.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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IL-2-only culture, the frequency of this clonotype dropped
to 2%. In ND006, a dominant clonotype CALWEV---
QELG, fell from 13.4% in PBMC, to <3% in the IL-2-only
culture. For ND006, the total frequency of peripheral Vγ2-
Jγ1.2 T cells dropped from 87% to 17.4% following IL-2
treatment (data not shown). For ND001, the dominant
PBMC clonotypes, CALW---SR---ELG and CALWE---A---
ELG, were still present at high frequencies after IL-2 but
other IPP-inducible clonotypes including CALWEV---
QELG, CALWE---T---QELG and CALWE---TE---QELG were
distinctly low after IL-2 treatment.
CD56+ Vγ2Vδ2 cells clones are cytotoxic for Daudi cells
So far, studies have focused on the Vγ2 repertoire as a
marker for clonality. Next, we examined individual bio-
logical clones of Vγ2Vδ2 T cells to confirm the link
between CD56 expression and cytotoxicity.
Our initial efforts to obtain clones used PHA stimulation
followed by limiting dilution on feeder cells [15]. We
acquired a small number of clones with this method--9/
27 being CD56+ and 18/27 being CD56-. The Vγ2 chain
sequences were determined and in each case, the pheno-
Multiple Vγ2 nucleotypes comprise individual public clonotypes Figure 3
Multiple Vγ2 nucleotypes comprise individual public clonotypes. Public clonotypes are usually encoded by more than 
one circulating nucleotype. The amino acid sequences appear in the vertical box at the left. The possible nucleotypes that 
encode this clonotype are shown in the horizontal boxes as nucleotide sequences; the hypervariable or N nucleotides are 
shown in bold type. The histograms show the abundance of each nucleotype (as a proportion of all sequences in the CD56+ or 
CD56- samples) among IPP-expanded cell lines generated from PBMC collected in 2007 or 2008. The bar height represents the 
total nucleotype abundance; the dark shaded portion indicates the fraction of sequences in the CD56+ subset and the light 
shaded region shows the fraction of nucleotypes in the CD56- subset. The label "ND" indicates that nucleotype was "not 
detected" in the 2007 or 2008 cell lines.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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type (CD56 positive or negative) and the Vγ2 sequence of
the clone matched what was found in the population
analysis (data not shown). Unfortunately, none of these
clones could be expanded to the levels needed for cytotox-
icity assays. We repeated the cloning using IPP stimula-
tion and plating on feeder cells. After multiple cloning
efforts with PBMC from two different donors (N0001 and
N0019), we obtained 15 clones that were phenotyped,
had Vγ2 chain sequencing to confirm clonality and were
used for cytotoxicity assays. Every clone expressed CD56
above the mean fluorescence intensity of 30, which is the
usual cut-off for cell separations, suggesting that cells
from the CD56+ subset had a higher cloning efficiency
compared to CD56- cells. The clones all expressed
NKG2D, a receptor required for Vγ2Vδ2 T cell cytotoxicity
[21,22], with the percentage of NKG2D+ cells varying
from 16% to 82% of cloned cells (Figure 7B). With the
exception of clone 1-G10, all clones were cytotoxic for
Daudi cells. Further, each of the CD56+ clones had a Vγ2
sequence that was matched to a sequence found in the
CD56+ fraction of that donor's total Vγ2+ cell population.
Despite representing approximately 50% of the Vγ2Vδ2 T
cell population, the cloning studies produced few CD56-
clones and they could not be expanded. Cloning studies
showed that CD56 expression in clones was matched to
the same Vγ2 clonotypes observed in purified sub-popula-
tions, and all of the CD56+ clones were cytotoxic for
Daudi cell targets.
Multiple Vγ2 nucleotypes encode the public clonotype CALWEV---R---ELG Figure 4
Multiple Vγ2 nucleotypes encode the public clonotype CALWEV---R---ELG. Nucleotypes encoding the public clono-
type CALWEV---R---ELG are listed. Histograms show the abundance of each nucleotype in two distinct samples with dark 
shading indicating the proportion of CD56+ sequences and the light shading showing sequences in the CD56- fraction (as 
described for Figure 3). ND indicates a particular nucleotype was not found for those specimens.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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Discussion
The CD56 cell surface glycoprotein is a marker for cyto-
toxic Vγ2Vδ2 T cells [17]. Within the circulating T cell pop-
ulation, individual Vγ2Vδ2 T cells fell mostly into two
groups: precursor CTL effectors that express CD56 upon
activation and cells that do not express CD56. For each
human donor, cells identified by Vγ2 sequences mostly
showed the same propensity for CD56 expression in sam-
ples collected 1 year apart, arguing that this property is sta-
ble. Thus, CD56 is not regulated stochastically on Vγ2Vδ2
T cells, but reflects a stable phenotype of individual cells
in the population.
The next step was to discern whether CD56 is expressed
on cells with unique TCR specificities. There was no fixed
relationship between individual public Vγ2 chains and
CD56 expression. Further, some of these chains defined
populations present in both CD56+ and CD56- fractions.
Individual nucleotypes showed a trend for appearing in
CD56+ or CD56- fractions but not both, arguing that the
capacity for CD56 expression was a pre-existing feature of
individual cells i.e., they were precursors.
The analysis of nucleotypes provided the surprising result
that unrelated donors express identical nucleotypes. Such
events are known for NKT cells where the invariant Vα24
chain is the germ-line sequence without deletions or N-
region additions [8]. For Vγ2 chains, conserved CDR3
regions may be due to limited deletion during recombina-
tion [23] and strong selection for these sequences since
Multiple nucleotypes encoding the canonical Vγ2 chain CALWEV---QELG Figure 5
Multiple nucleotypes encoding the canonical Vγ2 chain CALWEV---QELG. The clonotype CALWEV---QELG is des-
ignated as the canonical sequence because it can be expressed with N-region additions. However, this public clonotype is also 
encoded by multiple nucleotypes as shown here. Histograms show the proportion of each nucleotype in the total sequence set 
(bar height) for two distinct samples. Dark shading indicates the proportion of sequences in CD56+ cells while light shading 
refers to the proportion of sequences found in CD56- cells. ND indicates that a particular nucleotype was not found for those 
samples.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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IL-2 induces expression on Vγ2+ cells without expansion Figure 6
IL-2 induces expression on Vγ2+ cells without expansion. Ex vivo PBMC were collected from our 3 donors and depleted 
of CD56+ cells by magnetic cell separation. Samples were cultured for 14 days with IPP+IL-2 or IL-2 alone. Cells were col-
lected from the cultures at regular intervals and analyzed for Vγ2 and CD56 expression by FACS. The percentage of Vγ2+ cells 
in the cell lines are shown in Figure 6A. The ratio of CD56+ Vγ2+ to CD56- Vγ2- cells was calculated and plotted in Figure 6B. 
Samples that were treated with IL-2 alone are shown in gray, while black markings indicate IPP-expanded cultures. We also 
measured changes in Vγ2+ cells during 14 days after IPP+IL-2. For ND001, Vγ2+ cells went from 1.6 × 107 to 9.1 × 107 cells 
(5.7 fold increase), for ND006 the increase was from 1.2 × 107 to 6.7 × 107 cells (5.6 fold increase) and for ND019 the increase 
was from 1.8 × 107 to 8.4 × 107 (4.7 fold increase).BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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most of the N-region additions in these examples only
affect the wobble base and do not change the amino acid
sequence. There is strong selection for leucine, valine or
isoleucine at position 97 in the Vδ2 chain CDR3 region
and the conserved residues are believed important for
phosphoantigen recognition [24,25]. In our study, the
appearance of identical nucleotypes among unrelated
donors complicates the analysis. If a sequence can arise in
multiple donors, it seems likely that the same sequence
can arise more than once in a single donor. For public
nucleotypes, the individual Vγ2 chain sequence does not
necessarily identify a single clone and complex properties
must be expected.
The analysis of Vγ2 chain sequences showed overall, that
individual clones of Vγ2+ cells in PBMC either had or did
not have the capacity to express CD56 and become cyto-
toxic effectors. Whether this defines a lineage is unclear.
Among T cells, lineage generally defines events during
early cell differentiation. Recent studies in the mouse
showed the capacity for IL-17/IL-23 expression defined a
γδ T cell lineage [26]. The patterns for thymic CD27
expression and engagement with its ligand CD70, dictated
entry into a cytotoxic γδ T cell lineage in mice [27], argu-
ing that early events dictate the long-term outcome. There-
fore, in the mouse, γδ T cell cytotoxicity is lineage-
restricted. The human Vγ2Vδ2 repertoire contains few if
any, naïve cells as it is the product of extensive extrath-
ymic selection [18]. The CD56 marker is rarely expressed
in human cord blood γδ T cells (Cairo et al, unpublished)
and presumably reflects a subsequent developmental
stage. Our studies cannot explain whether the capacity for
CD56 expression arose early or late, and consequently, we
hesitate to describe precursors to the CD56+ subset as
comprising a lineage.
There was an intriguing trend between CD56 expression
and clonotype frequency. Presumably the result of strong
positive selection, the more abundant clonotypes tended
to express CD56. This may reflect the increased apoptosis-
resistance of CD56+ Vγ2Vδ2 cells [17], a trend also seen in
CD56+ αβ T cells. The result of selection is an oligoclonal
population of tumor effector cells that are stably main-
tained in the CD56+ fraction.
Whether Vγ2Vδ2 T cells belong to innate or acquired
immunity is an enduring question in this field [28]. With
a high proportion of cells expressing the Vγ2-Jγ1.2Vδ2
TCR there is an innate like response to phosphoantigen.
However, there is clear evidence for selection and amplifi-
cation of discrete subsets, including the Vγ2-Jγ1.2 rear-
rangement [14-16]. Our studies reported here show that
chronic selection produces a population with phosphoan-
tigen-specific TCR, but other mechanisms, likely operat-
ing before peripheral selection, dictate the potential for
cytotoxicity and CD56 expression. Thus, the Vγ2Vδ2 TCR
Table 2: Vγ2 clonotype frequencies in IL-2 treated cultures.
Clonotypes Ex Vivo IPP IL2
DONOR: ND001 2008 2008 2008
CALW SR ELG 34 21 25
CALWE A ELG 28 14 34
CALWE RK QELG 69 < 3
CALWEV RK LG <3 4 <3
CALWEV QELG <3 3 <3
CALWE T QELG <3 21 <3
CALWE TE QELG <3 10 <3
N 158 239 268
DONOR: ND006
CALWEV QELG 13 13 <3
CALWE AK ELG 91 0 < 3
CALWE A QELG 61 2 < 3
CALWEV R ELG 44 < 3
N 206 287 172
DONOR: ND019
CALWEV D ELG 36 23 <3
CALWE PQ QELG 57 < 3
CALWEV QELG 85 6
CALWEV R ELG <3 8 9
CALWE A QELG 97 1 8
CALWE IE QELG <3 5 <3
N 256 246 242
Vγ2 chains from donor PBMC, IPP-stimulated cell lines, and IL-2 only 
treated cells were sequenced. Individual Vγ2 clonotypes frequencies 
for stable clonotypes were calculated as a proportion of total 
sequences obtained from each donor sample. Any sequences present 
at a frequency below 3% are under the limits of detection for this 
assay. The total numbers of sequences analyzed for each sample are 
listed.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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Vγ2 T cell clones expressing CD56 are cytotoxic against Daudi cells Figure 7
Vγ2 T cell clones expressing CD56 are cytotoxic against Daudi cells. γδ T cell clones were generated expansion of a 
single cell by phosphoantigen in the presence of irradiated feeder cells. Expression of the Vγ2 chain of the TCR, CD56, and 
NKG2D were determined by flow cytometry. Figure 7A shows CD56 staining of a CD56+ Vγ2+ clone versus a CD56- Vγ2+ 
clone. Cytotoxicity of each clone was analyzed using a flow cytometry-based assay. Target Daudi cells were labeled with CFSE 
and cultured with cloned γδ cells at Effector:Target ratios of 10:1, 1:1, and 0.1:1. After 4 hours of incubation, the reactions 
were stopped with paraformaldehyde and PKH26-labeled Daudi cells were added to each tube. Specific lysis was calculated 
using the following formula: (CFSE-labeled control ÷ PKH26-labeled control) - (CFSE-labeled target ÷ PKH26-labeled refer-
ence) × 100. Assays were performed with triplicate samples and standard deviation was <15% of the mean. The specific lysis 
values at E:T of 10:1 are listed for each clone. Cytotoxicity panels for 3 representative clones showing high, medium, and low/
no lysis are also shown.BMC Immunology 2009, 10:50 http://www.biomedcentral.com/1471-2172/10/50
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is necessary for tumor cell cytotoxicity because cell activa-
tion by antigen is required to develop effector function.
However, cytotoxic and non-cytotoxic cells both prolifer-
ate in response to phosphoantigen. Owing to the greater
complexity in αβ TCR repertoire, it is difficult to perform
the same tracking studies, but it would be interesting to
learn whether epitope-specific CD8 αβ T cells also display
differences in CD56 expression that control cytotoxicity.
Conclusion
Prior to selection and amplification mechanisms that
shape the adult γδ T cell repertoire, individual clones are
committed to the cytotoxic or non-cytotoxic lineages. Lin-
eage commitment was not related to TCR specificity, as
cytotoxic and non-cytotoxic precursors responded simi-
larly to phosphoantigen stimulation. The mature popula-
tion of Vγ2Vδ2 T cells includes committed precursors
capable of expressing CD56 and cytolytic effector activity
against tumor cells.
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